Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials
By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore. Read More
|
|
|
Making sense of R&D data in a networked life science model
Aug 27 | eCliniqua Commentary | When researchers at the Cancer Vaccine Center (CVC) at Dana-Farber Cancer Institute (DFCI) began to study the cancer vaccine field, they gathered data from more than 645 vaccine trials, including cancer types, incidence, and survival rates, in order to identify relationships, trends and patterns.
|
|
Transforming Health Care: The Potential of Electronic Medical Records
Aug 23 | eCliniqua Commentary | The health care industry has long known the day would come when it would move to electronic medical records (EMRs), but has been slow to make this transition. Now those delays are over. The American Recovery and Reinvestment Act mandates adoption of EMRs by 2011, but providers needn’t take this as bad news. In fact, using EMRs across the health care spectrum will yield enormous benefits for providers and patients alike.
|
|
Orphan Drug Research Suddenly in Vogue: Aug 16
Orphan Drug Research Suddenly in Vogue: Aug 16
|
|
Orphan Drug Research Suddenly in Vogue
Aug 16 | eCliniqua | Interest in orphan drug research has picked up noticeably in recent months, with both Pfizer and GSK opening up R&D units devoted to rare diseases earlier this year. The biggest impetus may well be expiring patents on more commonly used drugs and no potential blockbusters in the pipeline, theorizes Peter Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD). Possibly, drugs developed for a rare disease can also be “leveraged” to treat more typical conditions.
|
|
Placing the Target User First in Clinical Trial Technology
Aug 16 | eCliniqua | In the past decade, clinical trial technology has undergone considerable evolution in its design, capability and deployment. From the early days of remote data capture, to full-suite clinical trial management solutions, this technologic evolution is redefining clinical research. Nevertheless, clinical research technology has suffered from significant resistance at the study site level, and this can be traced to a deficit in one basic element: user-centered design.
|
|
Children's Hospital of Philadelphia Creates Free Adverse Event App
Aug 12 | News Brief | The Children's Hospital of Philadelphia has created a free app for the iPhone to help doctors record side effects in clinical trials.
|
|
ICON Appoints Global Head for Infectious Disease
Jul 27 | News Brief | ICON has announced the appointment of Jonathan M Fishbein, M.D. as Vice President and Global Head for the Infectious Disease Therapeutic Area Group at ICON Clinical Research.
|
|
Health Decisions Names New CTO
Jul 27 | News Brief | Health Decisions has named Bryan Minihan as its new Chief Technology Officer. Minihan will strengthen Health Decisions’ proprietary HD360° technology platform
|
|
DIA: Innovation, Issues-Driven, Upbeat
DIA: Innovation, Issues-Driven, Upbeat
|
|
Early Trial Planning Solutions & DIA News: Jun 21
Early Trial Planning Solutions & DIA News
|
Remote Data Capture:Acquisition and Analysis See why Electronic Data Capture (EDC) is gaining traction in the pharmaceutical
clinical trials arena. Today approximately half of all clinical trials are conducted
electronically, and the figure is rapidly rising. Report includes contributions from
Oracle Health Sciences, Pfizer, PPD, and C3i.
The Role of Analytics in Transforming Healthcare Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders. Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.
BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are: - Potentially stunning return on investment at multiple levels.
- A 500%, or better, increase in application development time by directly executing business requirements
- Improved customer retention
- A 50% possible reduction in training time
Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.
Bio-IT World & CHI
Impact of the 1000 Genomes Project on the Next Wave of Pharmacogenomic Discovery
 Interview with M. Eileen Dolan, Ph.D., Professor, Medicine, University of Chicago and Speaker at Next-Generation Sequencing Data Management, September 27-29, 2010, Providence, RI
The 1000 Genomes Project aims to provide detailed genetic variation data on >1000 genomes from worldwide populations using the next-generation sequencing technologies. Some of the samples utilized for the 1000 Genomes Project are the International Hap-Map samples that are composed of lymphoblastoid cell lines (LCLs) derived from individuals of different world populations. The detailed map of human genetic variation promised by the 1000 Genomes project will allow a more in-depth analysis of the contribution of genetic variation to drug response. Future studies utilizing this new resource can greatly enhance our understanding of the genetic basis of drug response and other complex traits.
Download Now
More Podcasts
Software Engineer – Computational Biology Center
Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.
Apply: www.mskcciscareers.org. Equal opportunity and affirmative action employer.
|
|
|